What is the appropriate dosing of Mounjaro (tirzepatide) in a patient with an eGFR of 45 mL/min/1.73 m²?

Mounjaro (Tirzepatide) Dosing at eGFR 45 mL/min/1.73 m²

No dose adjustment is required for Mounjaro (tirzepatide) in a patient with an eGFR of 45 mL/min/1.73 m²—use standard dosing starting at 2.5 mg weekly and titrate as clinically indicated.

Key Evidence

The FDA label for Mounjaro contains no renal dose adjustments or contraindications based on kidney function 1. This is supported by pharmacokinetic data showing that renal impairment—including moderate impairment (eGFR 30-59 mL/min/1.73 m²)—does not significantly alter tirzepatide exposure 2. The study found only a 25-29% increase in drug exposure in moderate renal impairment, which is not clinically significant enough to warrant dose modification.

Clinical Context for GLP-1 Receptor Agonists in CKD

Your patient's eGFR of 45 mL/min/1.73 m² places them in CKD Stage 3b (moderately to severely decreased kidney function). The KDIGO 2022 guidelines specifically address GLP-1 receptor agonists in this population 3:

• Dulaglutide: No dose adjustment needed; can be used with eGFR >15 mL/min/1.73 m²
• Liraglutide: No dose adjustment needed (limited data in severe CKD)
• Semaglutide (injectable and oral): No dose adjustment needed (limited data in severe CKD)

Tirzepatide follows this same pattern. The 2020 Endocrine Reviews guideline confirms that GLP-1 receptor agonists like dulaglutide and liraglutide require no dose adjustment at this level of kidney function 4.

Practical Dosing Algorithm

Start with 2.5 mg subcutaneously once weekly for 4 weeks, then:

• Titrate to 5 mg weekly if additional glycemic control or weight loss is needed and the initial dose is well-tolerated
• Further escalation to 7.5 mg, 10 mg, 12.5 mg, or 15 mg can occur at 4-week intervals based on clinical response
• Monitor eGFR at baseline and periodically (every 3-6 months is reasonable given the CKD stage) 5

Important Monitoring Considerations

Watch for gastrointestinal adverse effects, which are the most common side effects and may be more pronounced in patients with CKD 2. These include nausea, vomiting, and diarrhea. If severe GI symptoms occur, they could theoretically affect volume status and transiently impact kidney function.

A reversible decrease in eGFR may occur when initiating tirzepatide (similar to SGLT2 inhibitors), but this is generally not an indication to discontinue therapy 5. Recent data from SURPASS-CVOT showed that tirzepatide actually slowed eGFR decline compared to dulaglutide, with a between-group difference of 0.29 mL/min/1.73 m² per year in the overall population 6.

Kidney-Protective Effects

Emerging evidence suggests tirzepatide may have renoprotective benefits. In the SURPASS-CVOT trial, tirzepatide reduced the risk of major kidney events by 23% compared to dulaglutide 6. Real-world data also shows improvements in kidney function markers, with one study demonstrating increased eGFR and reduced proteinuria after 3 months of treatment 7, 8.

Common Pitfalls to Avoid

1. Do not reduce the dose unnecessarily based solely on eGFR of 45—this is not required and may compromise therapeutic efficacy
2. Do not withhold tirzepatide during acute illness, prolonged fasting, or surgery due to ketosis risk (though temporary discontinuation is reasonable in these settings) 5
3. Do not forget to adjust other diabetes medications (particularly insulin or sulfonylureas) to prevent hypoglycemia when adding tirzepatide 5
4. Monitor for volume depletion if the patient is on diuretics, as GI side effects combined with diuretic use could affect kidney function 5

Drug Interactions

If your patient is on oral contraceptives, advise switching to non-oral contraception or adding barrier methods for 4 weeks after initiation and after each dose escalation, as tirzepatide may reduce oral contraceptive efficacy 1.